Your session is about to expire
← Back to Search
Monoclonal Antibodies
Cholesterol-Lowering Medication for Heart Attack (EVOLVE-MI Trial)
Phase 4
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age greater than or equal to 18 years
Hospitalized for primary reason of NSTEMI or STEMI due to presumed atherosclerotic disease
Must not have
Participants requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to week 12
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved
No Placebo-Only Group
Summary
This trialstudies if a cholesterol-lowering medication can reduce heart attack, stroke and death in people hospitalized for a heart attack.
Who is the study for?
This trial is for adults over 18 who are hospitalized due to a heart attack (NSTEMI or STEMI) presumed to be caused by plaque buildup in the arteries. It's not open to those needing intensive support like pumps or drugs for blood pressure at screening, or if their heart damage isn't due to artery issues.
What is being tested?
The EVOLVE-MI study tests whether giving Evolocumab with standard cholesterol management right after a heart attack is better than just routine care alone. The goal is to see if this can reduce further heart attacks, strokes, surgeries on arteries, and deaths.
What are the potential side effects?
Evolocumab may cause reactions where it's injected, flu-like symptoms, back pain, high blood pressure episodes, and allergic reactions. Side effects vary from person to person.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I was hospitalized for a heart attack caused by blocked arteries.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I need machines or drugs to help my heart and blood pressure work.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to week 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Percentage Change From Baseline in LDL-C
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Evolocumab + Routine Lipid ManagementExperimental Treatment2 Interventions
Participants will receive open-label evolocumab every 2 weeks (Q2W) plus routine lipid management.
Group II: Routine Lipid ManagementActive Control1 Intervention
Participants will receive routine lipid management per standard of care (SoC).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Evolocumab
2011
Completed Phase 4
~13010
Find a Location
Who is running the clinical trial?
AmgenLead Sponsor
1,433 Previous Clinical Trials
1,389,142 Total Patients Enrolled
Colorado Prevention CenterOTHER
12 Previous Clinical Trials
16,634 Total Patients Enrolled
MDStudy DirectorAmgen
971 Previous Clinical Trials
933,314 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I have heart damage not caused by blocked arteries, like from an infection or uncontrolled high blood pressure.I need machines or drugs to help my heart and blood pressure work.I was hospitalized for a heart attack caused by blocked arteries.
Research Study Groups:
This trial has the following groups:- Group 1: Evolocumab + Routine Lipid Management
- Group 2: Routine Lipid Management
Awards:
This trial has 3 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Heart Attack Patient Testimony for trial: Trial Name: NCT05284747 — Phase 4
Share this study with friends
Copy Link
Messenger